Final Program

WEDNESDAY • MAY 18 385
P1012
P1013
P1014
P1015
P1016
P1017
P1018
P1019
P1020
P1021
P1022
Facilitator:
P1023
P1024
Combination Therapy for Pulmonary Arterial Hypertension. A
Systematic Review and Meta-Analysis/B.D. Fox, O. Straichman,
D. Langleben, A. Shimony, M.R. Kramer, Petach Tikva, Israel,
p.A7377
Noninvasive Echocardiography Assessment of Group 3 Severe
Pulmonary Hypertension/R. Jiang, C. Wu, B. Pudasaini, L. Wang,
Q.-H. Zhao, S.-G. Gong, J. He, P. Yuan, Z.-C. Jing, J.-M. Liu,
Shanghai, China, p.A7378
Establishing the Effect of Targeted Therapies on Diffusing
Capacity in Patients with Pulmonary Arterial Hypertension
(PAH)/L. Thirugnanasothy, S. Sithamparanathan, J. Lordan, A.J.
Fisher, G. MacGowan, G. Parry, P.A. Corris, Newcastle-upon-Tyne,
United Kingdom, p.A7379
Effects of Spironolactone in Pulmonary Arterial Hypertension:
Results of SPIRO Study/Z. Safdar, E. Tamez, A. Thakur, M.
Entman, A. Basant, A. Frost, Bellaire, TX, p.A7380
Reduced Venous Vessel Density in Pre-Capillary Pulmonary
Hypertension/M. Pienn, C. Payer, M. Urschler, C.
Salvan-Schaschl, R. Neuwirth, R. Stollberger, G. Kovacs, V. Foris,
A. Olschewski, H. Olschewski, Z. Balint, Graz, Austria, p.A7381
A Proof of Concept Study of Human Volunteers and Pulmonary
Hypertension Patients Breathing Nitric Oxide Produced by
Electrical Pulsed Discharge/L. Berra, J. Rodriguez-Lopez, B. Yu,
E. Rezoagli, S. Strelow, D. Fisher, R.N. Channick, W.M. Zapol,
Boston, MA, p.A7382
Protocols for Identification of Portopulmonary Hypertension in
Liver Transplant Candidates: The Emory Experience/P.
Rajaram, J.P. Wedd, M.R. Fisher, Atlanta, GA, p.A7383
The Relationship Between the Modified Borg Scores and
Hospitalization in Pulmonary Arterial Hypertension/D.
Banerjee, J. Kamuren, G. Baird, A. Palmisciano, I. Krishnan, M.
Whittenhall, J.R. Klinger, C.E. Ventetuolo, Providence, RI, p.A7384
Clinical Characteristics and Treatment Outcomes of Primary
Pulmonary Artery Sarcoma in Korea/Y. Lee, D.S. Lee, S.-D. Lee,
J.S. Lee, Seoul, Korea, Republic of, p.A7385
Chronic Thromboembolic Pulmonary Hypertension and
Schizophrenia/H. Suzuki, K. Sugimura, S. Tatebe, T. Aoki, H.
Shimokawa, Sendai, Japan, p.A7386
Usefulness of Echocardiography in Predicting Survival Benefit
of Sildenafil in Patients with Interstitial Lung Disease/Y. Tomita,
A. Miyamoto, K. Kishi, S. Ishiwata, M. Ohno, Tokyo, Japan,
p.A7387
J.M. Elwing, MD, Cincinnati, OH
Riociguat as a Bridge Therapy for Balloon Pulmonary
Angioplasty in Patients with Chronic Thromboembolic
Pulmonary Hypertension/J. Ueda, T. Ogo, S. Fukui, A. Tsuji, Y.
Morita, T. Fukuda, S. Yasuda, H. Ogawa, N. Nakanishi, Suita,
Japan, p.A7388
Baseline Demographics of the Prospective, Multicenter,
Single-Arm, Open-Label, Phase IV MOTION Study of Riociguat
in Pulmonary Arterial Hypertension/N. Sood, A. Aranda, S.
Mobin, D. Platt, G. O’Brien, C. Satler, Columbus, OH, p.A7389
P1025
P1026
P1027
P1028
P1029
P1030
P1031
P1032
P1033
P1034
Facilitator:
P1035
Endothelial Microparticles as Biomarkers of Pulmonary
Hypertension in Systemic Sclerosis/M.R. Lammi, L.A. Saketkoo,
S. Okpechi, D. Wyczechowska, N. Bauer, K. Pyakurel, M. Ghonim,
S. Saito, V. Jaligam, B. DeBoisblanc, A.H. Boulares, New Orleans,
LA, p.A7390
Internal Jugular Versus Femoral Vein Access for Right Heart
Catheterization in the Evaluation of Pulmonary Hypertension.
Does the Site of Access Matter?/L. Cagino, A. Ataya, L.
Richards, X. Wu, H. Alnuaimat, Gainesville, FL, p.A7391
Red Cell Distibution Width as a Biomarker of Pulmonary
Hypertension/L. Petrauskas, L.A. Saketkoo, S. Saito, V. Jaligam,
B. DeBoisblanc, M.R. Lammi, New Orleans, LA, p.A7392
Riociguat for the Treatment of Pulmonary Arterial
Hypertension and Chronic Thromboembolic Pulmonary
Hypertension: Real-Life Data From the EXPERT Registry/H.
Gall, H.-A. Ghofrani, M.M. Hoeper, M. Humbert, M.-A. Gomez
Sanchez, D. Pittrow, M. Halank, E. Grunig, H. Wirtz, H. Klose, R.
Ewert, T.J. Lange, J. Klotsche, J.-L. Vachiery, J.E. Nielsen-Kudsk,
R.J. Snijder, R. Mascherbauer, S. Ulrich, J. Loffler-Ragg, V. Cottin,
I. Tsangaris, A. Peacock, C. Meier, M. Brunn, G. Simonneau,
Giessen, Germany, p.A7393
Assessment of Right Ventricular Systolic Function in Patients
with Precapillary Pulmonary Hypertension Using Simple
Echocardiographic Parameters: A Comparison with Cardiac
Magnetic Resonance Imaging/O.A. Spruijt, M.C. Di Pasqua, H.J.
Bogaard, F. Oosterveer, J.T. Marcus, A. Vonk-Noordegraaf, L.
Handoko, Amsterdam, Netherlands, p.A7394
DLCO Is a Superior Screening Tool for PAH Compared to
NT-proBNP in Subjects with HIV/R.R. Vanderpool, M.G. Risbano, N.
Leo, C. Kessinger, L. Kingsley, Y. Zhang, F.C. Sciurba, T.N. Bachman,
M.A. Simon, M.T. Gladwin, A.M. Morris, Pittsburgh, PA, p.A7395
OPsumitr USers Registry (OPUS): Insights into the Safety and
Tolerability of Opsumitr/N.H. Kim, K.M. Chin, E. Muros-Le
Rouzic, M. Brand, M. Selej, R.N. Channick, V.V. McLaughlin, San
Diego, CA, p.A7396
The Qutenza (8% Capsaicin) Patch for Disabling Treprostinil
Infusion Site Pain/A. Light, K. Frutiger, K. Wessman, A. Heiniger,
R.J. White, Rochester, NY, p.A7397
Development of the United States Chronic Thromboembolic
Pulmonary Hypertension (CTEPH) Registry/K.M. Kerr, W.R.
Auger, R.L. Benza, R.N. Channick, K.M. Chin, R.D. Davis, C.G.
Elliott, A.Z. LaCroix, M.M. Madani, V. McLaughlin, M.H. Park, San
Diego, CA, p.A7398
Characteristics and Survival of Patients with Systemic Lupus
Erythematosus Associated with Pulmonary Arterial
Hypertension/J.L. Hernandez-Oropeza, M.A. Cacho-Diaz, J.D.J.
Rodriguez-Andoney, M. Moncada-Navas, E. Villegas-Antelo, E.
Rivero-Sigarroa, G. Dominguez-Cherit, Mexico, Mexico, p.A7399
A. Vaidya, MD, Philadelphia, PA
Relative Importance of Hemodynamics, Pulmonary Mechanics,
Body Habitus, Demographics, and Time to Diagnosis and
Treatment in Predicting 6 Minute Walk Test Results Before and
After Treatment in Patients with Pulmonary Arterial Hypertension/
C. Pena Orbea, N. Quesada, R. Lenhardt, Chicago, IL, p.A7400
WEDNESDAY MORNING
ATS 2016 • San Francisco